Subglottic stenosis (SGS) is a known complication of granulomatosis with polyangiitis (GPA). We investigated the impact of medical and surgical interventions on the surgical dilation interval and characterized patients with glottic involvement.
Study Design
A retrospective chart review of patients with GPA-associated SGS was performed from 2010 to 2019.
Setting
Tertiary academic medical center.
Methods
The impact of medical and surgical interventions on dilation interval was assessed. The prevalence of glottic involvement was assessed, and clinical characteristics and outcomes were compared with patients without glottic involvement.
Results
A total of 39 patients with GPA-associated SGS were analyzed. Dilation intervals in patients receiving leflunomide (n = 4; median, 484 days; 95% CI, 405-1099) were greater than in those not receiving leflunomide (median, 155 days; 95% CI, 48-305; P = .033). The surgical technique used did not affect dilation interval. Patients with glottic involvement (n = 13) had a greater incidence of dysphonia (13/13 vs 15/26 [58%], P = .007) and a shorter dilation interval with involvement (median, 91 days; interquartile range, 70-277) versus without involvement (median, 377 days; interquartile range, 175-1148; hazard ratio, 3.38; 95% CI, 2.26-5.05; P < .001). Of 13 patients, 8 (62%) did not have glottic involvement on first presentation.
Conclusion
Although GPA is classically thought to affect the subglottis, it also involves the glottis in a subset of patients. These patients have greater complaints of dysphonia and require more frequent surgery. Systemic therapy may increase dilation intervals. In this preliminary study, patients taking leflunomide demonstrated an improvement, highlighting the need for further study of immunosuppression regimens in the treatment of GPA-associated SGS.
GrecoAMarinelliCFusconiM, et al. Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol. 2016;29(2):151-159.
2.
LutaloPMKD’CruzDP. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener’s granulomatosis). J Autoimmun. 2014;48-49:94-98.
3.
BlackabeyVGanRWCBuglassHKaulVWardVMM. Granulomatosis with polyangiitis causing subglottic stenosis—two cases and their management. AME Case Rep. 2018;2:17.
4.
TaylorSCClayburghDRRosenbaumJTSchindlerJS.Progression and management of Wegener’s granulomatosis in the head and neck. Laryngoscope. 2012;122(8):1695-1700.
5.
Martinez Del PeroMJayneDChaudhryASivasothyPJaniP. Long-term outcome of airway stenosis in granulomatosis with polyangiitis (Wegener granulomatosis): an observational study. JAMA Otolaryngol Head Neck Surg. 2014;140(11):1038-1044.
6.
TrimarchiMSinicoRATeggiRBussiMSpecksUMeroniPL.Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener’s). Autoimmun Rev. 2013;12(4):501-505.
7.
JordanNPVermaHSiddiquiAMorrisonGAD’CruzDP.Morbidity and mortality associated with subglottic laryngotracheal stenosis in granulomatosis with polyangiitis (Wegener’s granulomatosis): a single-centre experience in the United Kingdom. J Laryngol Otol. 2014;128(9):831-837.
8.
Marroquín-FabiánERuizNMena-ZúñigaJFlores-SuárezLF.Frequency, treatment, evolution, and factors associated with the presence of tracheobronchial stenoses in granulomatosis with polyangiitis: retrospective analysis of a case series from a single respiratory referral center. Semin Arthritis Rheum. 2019;48(4):714-719.
9.
QuinnKAGelbardASibleyC, et al. Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. Rheumatology (Oxford). 2019;58(12):2203-2211.
10.
Martinez Del PeroMRasmussenNChaudhryAJaniPJayneD. Structured clinical assessment of the ear, nose and throat in patients with granulomatosis with polyangiitis (Wegener’s). Eur Arch Otorhinolaryngol. 2013;270(1):345-354.
11.
MonachPA. L25. Medical treatment of subglottic stenosis in granulomatosis with polyangiitis (Wegener’s). La Presse Médicale. 2013;42(4, pt 2):575-576.
12.
LangfordCASnellerMCHallahanCW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum. 1996;39(10):1754-1760.
13.
GluthMBShinnersPAKasperbauerJL.Subglottic stenosis associated with Wegener’s granulomatosis. Laryngoscope. 2003;113(8):1304-1307.
14.
MiloslavskyEMLuNUnizonyS, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener’s): distinct patient subsets. Arthritis Rheumatol. 2016;68(12):2945-2952.
15.
StoneJH; Wegener’s Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum. 2003;48(8):2299-2309.
16.
GadkareeSKPandianVBestS, et al. Laryngotracheal stenosis: risk factors for tracheostomy dependence and dilation interval. Otolaryngol Head Neck Surg. 2017;156(2):321-328.
17.
MalmI-JMenerDJKimJSeoPKimYJ.Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab. Otolaryngol Head Neck Surg. 2014;150(1):68-72.
18.
GuardianiEMoghaddasHSLesserJ, et al. Multilevel airway stenosis in patients with granulomatosis with polyangiitis (Wegener’s). Am J Otolaryngol. 2015;36(3):361-363.
19.
TerrierBDechartresAGirardC, et al. Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience. Rheumatology (Oxford). 2015;54(10):1852-1857.
20.
GirardCCharlesPTerrierB, et al. Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegener’s): a report on 26 cases. Medicine (Baltimore). 2015;94(32):e1088.
21.
GardnerGM.Posterior glottic stenosis and bilateral vocal fold immobility: diagnosis and treatment. Otolaryngol Clin North Am. 2000;33(4):855-878.
22.
MorcilloAWinsRGómez-CaroAParadelaMMolinsLTarrazonaV.Single-staged laryngotracheal reconstruction for idiopathic tracheal stenosis. Ann Thorac Surg. 2013;95(2):433-439.
23.
Reinhold-KellerEBeugeNLatzaU, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000;43(5):1021-1032.
24.
StoneJHMerkelPASpieraR, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232.
25.
HenesJCFritzJKochS, et al. Rituximab for treatment-resistant extensive Wegener’s granulomatosis—additive effects of a maintenance treatment with leflunomide. Clin Rheumatol. 2007;26(10):1711-1715.
26.
LuqmaniRA.State of the art in the treatment of systemic vasculitides. Front Immunol. 2014;5:471.
27.
GauseAMetzlerCReinhold-KellerEGrossWL. Leflunomide therapy for autoimmune diseases. In: SticherlingMChristophersE, eds. Treatment of Autoimmune Disorders. Springer; 2003:43-48.
28.
HazlewoodGSMetzlerCTomlinsonGA, et al. Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis. Joint Bone Spine. 2014;81(4):337-341.
29.
Grygiel-GórniakBLimphaiboolNPerkowskaKPuszczewiczM.Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features. Postgrad Med. 2018;130(7):581-596.
30.
ComarmondCCacoubP.Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev. 2014;13(11):1121-1125.
31.
CalichALPuéchalXPugnetG, et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener’s): results of a single-center cohort study on 66 patients. J Autoimmun. 2014;50:135-141.
32.
GouverisHKaraiskakiNKoutsimpelasDChongolwatanaCMannW.Treatment for adult idiopathic and Wegener-associated subglottic stenosis. Eur Arch Otorhinolaryngol. 2013;270(3):989-993.
33.
Solans-LaquéRBosch-GilJCanelaMLorenteJPallisaEVilardell-TarrésM.Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Lupus. 2008;17(9):832-836.
34.
CharlsonMEPompeiPAlesKLMacKenzieCR.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
35.
BelafskyPCMouadebDAReesCJ, et al. Validity and reliability of the Eating Assessment Tool (EAT-10). Ann Otol Rhinol Laryngol. 2008;117(12):919-924.
36.
van der MolenTWillemseBWMSchokkerSten HackenNHTPostmaDSJuniperEF.Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003;1:13.
37.
HogikyanNDSethuramanG.Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice. 1999;13(4):557-569.
38.
HseuAFBenningerMSHaffeyTMLorenzR.Subglottic stenosis: a ten-year review of treatment outcomes. Laryngoscope. 2014;124(3):736-741.
39.
AmorimLDCaiJ.Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol. 2015;44(1):324-333.
40.
KellyPJLimLL-Y. Survival analysis for recurrent event data: an application to childhood infectious diseases. Stat Med. 2000;19(1):13-33.
41.
MetzlerCFinkCLamprechtPGrossWLReinhold-KellerE.Maintenance of remission with leflunomide in Wegener’s granulomatosis. Rheumatology (Oxford). 2004;43(3):315-320.
42.
FeinsteinAJGoelARaghavanG, et al. Endoscopic management of subglottic stenosis. JAMA Otolaryngol Head Neck Surg. 2017;143(5):500-505.
43.
LavrysenEHensGDelaerePMeulemansJ.Endoscopic treatment of idiopathic subglottic stenosis: a systematic review. Front Surg. 2020;6:75.
44.
RoedigerFCOrloffLACoureyMS.Adult subglottic stenosis: management with laser incisions and mitomycin-C. Laryngoscope. 2008;118(9):1542-1546.
45.
ShabaniSHoffmanMRBrandWTDaileySH.Endoscopic management of idiopathic subglottic stenosis: factors affecting inter-dilation interval. Ann Otol Rhinol Laryngol. 2017;126(2):96-102.
46.
VolggerVMannSLEnglhardASBerghausA. An eleven-year review on treatment outcome after endoscope-based and open surgery for subglottic stenosis. In: Laryngo-rhino-otologie. Vol 97. Georg Thieme Verlag KG; 2018:10159.
47.
CataneoDCXimenesAMGCataneoAJM. Mitomycin C in the endoscopic treatment of tracheal stenosis: a prospective cohort study. J Bras Pneumol. 2018;44(6):486-490.
48.
DionGRChapaJSDLBettenhausenWDominguezLMSimpsonCB.Differing progression to posterior glottic stenosis in autoimmune and idiopathic subglottic stenosis. Laryngoscope. Published online September9, 2020. doi:10.1002/lary.29085
49.
HoasjoeDKFranklinSWAarstadRFDayTAStuckerFJ.Posterior glottic stenosis mechanism and surgical management. Laryngoscope. 1997;107(5):675-679.
50.
HillelATKaratayli-OzgursoySSamadI, et al. Predictors of posterior glottic stenosis: a multi-institutional case-control study. Ann Otol Rhinol Laryngol. 2016;125(3):257-263.
51.
RasmussenN. L24. Local treatments of subglottic and tracheal stenoses in granulomatosis with polyangiitis (Wegener’s). Presse Med. 2013;42(4, pt 2):571-574.
52.
KucukHTecerDGokerB, et al. Platelet/lymphocyte ratio and mean platelet volume in patients with granulomatosis with polyangiitis. Adv Rheumatol. 2019;60(1):4.
53.
TomassonGGraysonPCMahrADLavalleyMMerkelPA.Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis. Rheumatology (Oxford). 2012;51(1):100-109.
54.
VerstocktBBossuytXVanderschuerenSBlockmansD.There is no benefit in routinely monitoring ANCA titres in patients with granulomatosis with polyangiitis. Clin Exp Rheumatol. 2015;33(2, suppl 89):S-72-76.
55.
HoganPCPO’ConnellRMScollardSBrowneEHackettEEFeigheryC. Biomarkers predict relapse in granulomatosis with polyangiitis. J Biomark. 2014;2014:1-4.
56.
DaumTESpecksUColbyTV, et al. Tracheobronchial involvement in Wegener’s granulomatosis. Am J Respir Crit Care Med. 1995;151(2):522-526.
